Abstract
99mTc-MIBI (Sestamibi) was originally developed for myocardial perfusion studies. The agent also may be used for the depiction and characterization of tumors. Performing such examinations has shown uptake in skeletal structures in several patients suggesting bone engagement of the disease which later was excluded. Retrospective evaluation of 44 examinations with99mTc-MIBI performed in order to localize diseased parathyroid in patients with suspected hyperparathyroidism showed skeletal activity in 21 (48%) patients. Although these patients represent a selected group, the observation indicates a mechanism for skeletal accumulation of this radiopharmaceutical. Evaluation of another 13 normocalcemic patients undergoing whole-body registration for malignancy staging or to assess lower extremity ischemia with99mTc-MIBI showed skeletal activity in 6 (46%) patients. Complementary mouse experiments confirmed skeletal uptake of99mTc-MIBI, where most of the activity is taken up by the red bone marrow. It is concluded that homogeneous, diffuse weak skeletal activity at examination with99mTc-MIBI is a normal finding and does not indicate malignancy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Jones AG, Abrams MJ, Davison A, Brodack JW, Toothaker AK, Adelstein SJ, et al. Biological studies of a new class of technetium complexes: the hexakis (alkylisonitrile) technetium (I) cation.Int J Nucl Med Biol 11: 225–234, 1984.
Gerundini P, Savi A, Gilardi MC, Margonato A, Vicedomini G, Zecca L, et al. Evaluation in dogs and humans of three potential technetium-99m myocardial perfusion agents.J Nucl Med 27: 409–416, 1986.
Müller St, Guth-Tougelides B, Creutzig H. Imaging of malignant tumors with Tc-99m-MIBI SPECT.J Nucl Med 28: p562, 1987 (abstract).
Caner B, Kitapçi M, Aras T, Erbengi G, Ugur Ö, Bekdik C. Increased accumulation of hexakis(2-methoxyisobutylisonitrile)technetium(I) in osteosarcoma and its metastatic lymph nodes.J Nucl Med 32: 1977–1978, 1991.
O’Driscoll CM, Baker F, Casey MJ, Duffy GJ. Localization of recurrent medullary thyroid carcinoma with technetium-99m-methoxyisobutylisonitrile scintigraphy: A case report.J Nucl Med 32: 2281–2283, 1991.
Balon HR, Fink-Bennett D, Stoffer SS. Technetium-99m-sestamibi uptake by recurrent Hürthle cell carcinoma of the thyroid.J Nucl Med 33: 1393–1395, 1992.
Campeau RJ, Cronemer KA, Sutherland CM. Concordant uptake of Tc-99m sestamibi and Tl-201 in unsuspected breast tumor.Clin Nucl Med 17: 936–937, 1992.
Scott AM, Kostakoglu L, O’Brien JP, Straus DJ, Abdel-Dayem HM, Larson SM. Comparison of technetium-99m-MIBI and thallium-201-chloride uptake in primary thyroid lymphoma.J Nucl Med 33: 1396–1398, 1992.
Bagni B, Pinna L, Tamarozzi R, Cattaruzzi E, Marzola MC, Bagni I, et al. SPET imaging of intracranial tumours with99Tcm-sestamibi.Nucl Med Commun 16: 258–264, 1995.
Khalkali I, Cutrone JA, Mena IG, Diggles LE, Venegas RJ, Vargas HI, et al. Scintimammography: the complementary role of Tc-99m sestamibi prone breast imaging for the diagnosis of breast carcinoma.Radiology 196: 421–426, 1995.
Matsui R, Komori T, Narabayashi I, Namba R, Nakata Y, Tabuchi K, et al. Tc-99m sestamibi uptake by malignant lymphoma and slow washout.Clin Nucl Med 20: 352–356, 1995.
Ziegels P, Nocaudie M, Huglo D, Deveaux M, Detourmignies L, Wattel E, et al. Comparison of technetium-99m methoxyisobutylisonitrile and gallium-67 citrate scanning in the assessment of lymphomas.Eur J Nucl Med 22: 126–131, 1995.
Kao CH, Wang SJ, Chen CT, Yeh SH. Detection of esophageal carcinoma using Tc-99m MIBI SPECT imaging.Clin Nucl Med 19: 1069–1074, 1994.
Piwnicka-Worms D, Chiu ML, Budding J, Kronauge F, Kramer RA, Croop J. Functional imaging of multidrugresistant P-glycoprotein with an organotechnetium complex.Cancer Res 53: 977–984, 1993.
Coakley AJ, Kettle AG, Wells CP, O’Doherty MJ, Collins REC.99mTc-sestamibi—a new agent for parathyroid imaging.Nucl Med Commun 10: 791–794, 1989.
Taillefer R, Boucher Y, Potvin C, Lambert R. Detection and localization of parathyroid adenomas in patients with hyperparathyroidism using a single radionuclide imaging procedure with technetium-99m-sestamibi (double-phase study).J Nucl Med 33: 1801–1807, 1992.
Sayman HB, Urgancioglu I. Muscle perfusion with technetium-MIBI in lower extremity peripheral arterial disease.J Nucl Med 32: 1700–1703, 1991.
Sutter CW, Joshi MJ, Stadalnik RC. Noncardiac uptake of technetium-99m MIBI.Semin Nucl Med 24: 84–86, 1994.
Chiu ML, Kronauge JF, Piwnicka-Worms D. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis(2-methoxyisobutylisonitrile)technetium(I) in cultured mouse fibroblasts.J Nucl Med 31: 1646–1653, 1990.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jonsson, C., Jacobsson, H. Accumulation of99mTc-MIBI in bone marrow. Ann Nucl Med 10, 281–285 (1996). https://doi.org/10.1007/BF03164733
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF03164733